Senseonics Holdings Preparing for Notable Investor Engagements
Senseonics Holdings, Inc. (NYSE American: SENS), a pioneering medical technology firm, specializes in creating long-term implantable continuous glucose monitoring (CGM) systems, striving to improve the lives of those living with diabetes. The company is eager to share its advancements and strategic vision at several upcoming investor conferences.
Upcoming Conferences
Executives from Senseonics are scheduled to engage in two prominent investor conferences this November. These events will offer opportunities for in-depth discussions regarding the company’s latest developments and future goals in the glucose monitoring space.
Stifel 2024 Healthcare Conference
The first conference on the agenda is the Stifel 2024 Healthcare Conference, which will feature a corporate overview along with one-on-one meetings. This event is set for the 19th of November, where management will present their vision and updates at 9:10 AM ET.
Canaccord Genuity Medtech Forum
Following that, the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum will take place on November 21st. This conference will also consist of one-on-one meetings, allowing for tailored discussions pertaining to the company’s innovative technology and market positioning.
Accessing the Presentations
Investors interested in following Senseonics' presentations can expect to view both live and recorded sessions accessible via the Investor Relations section of Senseonics' official website. This initiative shows the company's commitment to transparency and their intention to keep stakeholders informed about their progress in the diabetes management sector.
The Innovative CGM Technology
At the heart of Senseonics’ mission is its innovative continuous glucose monitoring technology. The company has developed CGM systems that provide accurate glucose data for users actively managing diabetes. Their flagship products, Eversense® 365 and Eversense® E3, include a small sensor implanted completely under the skin. This groundbreaking design allows users to monitor their glucose levels throughout the day seamlessly.
Real-Time Data for Empowered Management
What sets Eversense apart is its ability to communicate with a smart transmitter that the user wears externally. Every five minutes, the glucose data is relayed directly to a mobile application on the user's smartphone. This real-time feedback is essential for proactive diabetes management, enabling users to make informed decisions regarding their health.
About Senseonics
Senseonics is at the forefront of diabetes healthcare, making substantial strides with their implantable glucose monitoring technology. Their dedicated focus on research and development ensures that they remain a key player in the medical technology landscape. As the diabetes community continues to evolve, Senseonics aims to meet the needs of patients with cutting-edge solutions that improve quality of life.
Contact Information for Investors
For additional inquiries, investors can connect with Jeremy Feffer of LifeSci Advisors by reaching out via email at Investors@senseonics.com. The company values its relationship with shareholders and strives to ensure that all questions are addressed promptly.
Frequently Asked Questions
What investor conferences will Senseonics participate in?
Senseonics will participate in the Stifel 2024 Healthcare Conference and the Canaccord Genuity Medtech Forum.
How does the Eversense CGM system work?
The Eversense CGM system involves a small sensor implanted under the skin that sends glucose readings to a smart transmitter worn on the body.
Where can I find the webcasts of the conferences?
Webcasts of the presentations will be available in the Investor Relations section of the Senseonics website.
What is the purpose of these investor conferences?
These conferences serve as platforms for Senseonics to discuss its business strategies, technological advancements, and future prospects with investors.
Who can I contact for investor relations?
For inquiries, investors can contact Jeremy Feffer at LifeSci Advisors via email at Investors@senseonics.com.
